For Health Care Professionals Outside the US

REVOLADE was well tolerated and was associated with few limitations to treatment1

  • No dose-limiting toxicities were observed, other than reversible transaminitis
    • This is similar to results seen in much larger efficacy and safety studies in ITP, despite a higher dose of REVOLADE used in SAA2
  • Eight (19%) patients had a new cytogenic abnormality reported while on therapy, including 5 patients who had changes in chromosome 71


1. REVOLADE Core Data Sheet. Version 2.4. 17 June 2019. 2. Desmond R, Townsley DM, Dumitriu B, et al. Eltrombopag restores trilineage hematopoiesis in refractory severe aplastic anemia that can be sustained on discontinuation of drug. Blood. 2014;123(12):1818-1825.